|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1997-2-21
|
|
pubmed:abstractText |
Balanol is a potent protein kinase C (PKC) inhibitor that is structurally composed of a benzophenone diacid, a 4-hydroxybenzamide, and a perhydroazepine ring. A number of balanol analogs in which the perhydroazepine moiety is replaced have been synthesized and their biological activities evaluated against both PKC and cAMP-dependent kinase (PKA). The results suggested that the activity and the isozyme/kinase selectivity of these compounds are largely related to the conformation about this nonaromatic structural element of the molecules.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
pubmed-author:BallasL MLM,
pubmed-author:BiggersC KCK,
pubmed-author:HallS ESE,
pubmed-author:HeerdingJ MJM,
pubmed-author:JagdmannG EGEJr,
pubmed-author:JanzenW PWP,
pubmed-author:JiangJ BJB,
pubmed-author:MenaldinoD SDS,
pubmed-author:MendozaJ SJS,
pubmed-author:WilsonJ WJW,
pubmed-author:YaoL SLS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
226-35
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety.
|
|
pubmed:affiliation |
Sphinx Pharmaceuticals, A Division of Eli Lilly & Company, Durham, North Carolina 27707, USA.
|
|
pubmed:publicationType |
Journal Article
|
